Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679751 | 0.87 | SCN9A (0.58) | SCN9ASCN5ASMN1; SMN2 | |
| SCHEMBL680538 | 0.87 | SCN9A (0.53) | SCN9AMRGPRX4SCN5A | |
| SCHEMBL16319549 | 0.87 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL679934 | 0.87 | SCN9A (0.57) | SCN9AMRGPRX4 | |
| SCHEMBL680193 | 0.85 | MRGPRX4 (0.61) | SCN9AMRGPRX4SCN5A | |
| SCHEMBL679866 | 0.84 | SCN9A (0.55) | SCN9AMRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL679816 | 0.83 | SCN9A (0.52) | SCN9AMRGPRX4 | |
| SCHEMBL680555 | 0.83 | SLC22A12 (0.50) | SCN9ASCN5ANPC1RAB9A | |
| SCHEMBL16319475 | 0.83 | SCN9A (0.62) | SCN9ASCN5A | |
| SCHEMBL678831 | 0.83 | BCL2L1 (0.52) | SCN9ASCN5ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 13/4885MRGPRX4 344/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.